Development and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2020	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
BARDA Agreement
Licenses Agreements [Line Items]
Additional committed fund receivable				$ 3,500,000
Committed fund receivable			$ 185,500,000
Reduction in committed fund receivable			8,800,000
Committed fund receivable			270,200,000
BARDA Agreement | Cerus Corporation | Maximum
Licenses Agreements [Line Items]
Co-investment by the company			1,400,000
FDA Agreement
Licenses Agreements [Line Items]
Contract agreement term		5 years
Total potential contract value		$ 11,100,000
DoD and IBAS Program Agreement | Minimum
Licenses Agreements [Line Items]
Total contract value	$ 9,100,000
DoD and IBAS Program Agreement | Maximum
Licenses Agreements [Line Items]
Total contract value	$ 17,800,000
Accounts Receivable | BARDA Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			5,600,000		$ 4,000,000
Accounts Receivable | FDA Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			500,000		200,000
Accounts Receivable | DoD and IBAS Program Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			3,700,000		500,000
Deferred Revenue | DoD and IBAS Program Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			$ 1,500,000
Other Current Assets | DoD and IBAS Program Agreement
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts					$ 100,000